Brian Masterson, MD
Psychiatry · Cincinnati, OHNPI 1053522359
Payments from drug & device makers
Across 248 payments — averaging $15.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$760
- Takeda Pharmaceuticals U.S.A., Inc.$484
- Lundbeck LLC$420
- Teva Pharmaceuticals USA, Inc.$409
- Abbott$387
- Neurocrine Biosciences, Inc.$263
- plus $1K from 28 others
What the payments were for
- Food & beverage$3,75597%
- Education$1203%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 54 | $760 |
| Takeda Pharmaceuticals U.S.A., Inc. | 34 | $484 |
| Lundbeck LLC | 31 | $420 |
| Teva Pharmaceuticals USA, Inc. | 20 | $409 |
| Abbott | 21 | $387 |
| Neurocrine Biosciences, Inc. | 17 | $263 |
| Amarin Pharma, Inc. | 8 | $141 |
| Johnson & Johnson | 8 | $136 |
| Novo Nordisk | 8 | $118 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $113 |
| Otsuka America Pharmaceutical, Inc. | 6 | $91 |
| Ironshore Pharmaceuticals Inc. | 4 | $64 |
| Shire North American Group Inc | 4 | $55 |
| Merck | 3 | $44 |
| Boehringer Ingelheim | 2 | $37 |
| Noven Therapeutics, LLC | 2 | $29 |
| Neos Therapeutics, LP | 2 | $28 |
| Axsome Therapeutics, Inc. | 1 | $27 |
| Edwards Lifesciences | 1 | $23 |
| Amgen | 1 | $21 |
| Vanda Pharmaceuticals Inc. | 1 | $21 |
| Sunovion Pharmaceuticals Inc. | 1 | $20 |
| Bayer | 1 | $20 |
| Novartis | 1 | $18 |
| Genentech USA, Inc. | 1 | $18 |
| AMAG Pharmaceuticals, Inc. | 1 | $16 |
| IBSA Pharma Inc. | 1 | $16 |
| Dexcom, Inc. | 1 | $15 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Eisai Inc. | 1 | $14 |
| Agile Therapeutics, Inc. | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$3,875 in reported general payments places this provider in the 85th percentile of 1,119 psychiatry providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 33 | $267,743 |
| TrintellixVortioxetine Hydrobromide | 16 | $19,572 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 29 | $2,784 |
| Duloxetine Hcl | 77 | $2,699 |
| Quetiapine Fumarate | 66 | $2,662 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 33 | $1,731 |
| Trazodone Hcl | 133 | $1,622 |
| Clonazepam | 130 | $1,562 |
| Clomipramine Hcl | 15 | $1,328 |
| Bupropion XlBupropion Hcl | 70 | $1,104 |
| Fluoxetine Hcl | 47 | $1,021 |
| Mirtazapine | 31 | $706 |
| Olanzapine | 15 | $553 |
| Amitriptyline Hcl | 27 | $538 |
| Escitalopram Oxalate | 51 | $530 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $263 | $267,74333 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $484 | $19,57216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,119 psychiatry providers in Ohio.
Other psychiatry in Cincinnati
- Henry NasrallahCincinnati$3.8M
- Caleb AdlerCincinnati$2M
- Paul KeckCincinnati$739K
- Peter BoxerCincinnati$718K
- Tracey SkaleCincinnati$674K
- Lesley ArnoldCincinnati$620K
- Stephen PolandCincinnati$440K
- Fabiano NeryCincinnati$391K
- Jeffrey StrawnCincinnati$336K
- Helen FarrellCincinnati$277K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.